Login to Your Account

Chi-Med, Astrazeneca report early, positive results for lung cancer candidate

By Cornelia Zou
Staff Writer

Wednesday, October 18, 2017

HONG KONG – Hutchison China Meditech Ltd. and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription